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Familial juvenile hyperuricemic nephropathy (FJHN), is an autosomal dominant renal disease characterized by
juvenile onset of hyperuricemia, gouty arthritis, and progressive renal failure at an early age. Using a genomewide
linkage analysis in three Czech affected families, we have identiﬁed, on chromosome 16p11.2, a locus for FJHN
and have found evidence for genetic heterogeneity and reduced penetrance of the disease. The maximum two-point
LOD score calculated with allowance for heterogeneity (HLOD) was 4.70, obtained at recombination fraction 0,
with marker D16S3036; multipoint linkage analysis yielded a maximum HLOD score of 4.76 at the same location.
Haplotype analysis deﬁned a 10-cM candidate region between ﬂanking markers D16S501 and D16S3113, exhibiting
crossover events with the disease locus. The candidate interval contains several genes expressed in the kidney, two
of which—uromodulin and NADP-regulated thyroid-hormone–binding protein—represent promising candidates
for further analysis.
Familial juvenile hyperuricemic nephropathy (FJHN),
or familial juvenile gouty nephropathy (FJGN [MIM
162000]), is an autosomal dominant renal disease char-
acterized by juvenile onset of hyperuricemia, gouty ar-
thritis, and progressive renal failure at an early age. This
condition was ﬁrst noted by Duncan and Dixon (1960).
More than 50 kindred originating from various ethnic
groups—Whites (for review, see Cameron et al. 1993),
Hungarians (Korom et al. 1979), Chinese (Lam and Peh
1995), Japanese (Saeki et al. 1995), and Polynesians
(Reiter et al. 1995)—have been described so far. The
biochemical hallmarks of the disease are hyperuricemia
and reduced fractional excretion of uric acid. Ultrasound
imaging studies show decreased kidney size, parenchy-
mal atrophy and abnormal echogenicity in a majority
of the patients, and infrequent occurrence of renal cysts
(Prieto and Berrocal 1994; Sebesta et al. 1994; Saeki et
al. 1995; Pavelka et al. 1996). Histological ﬁndings show
unspeciﬁc tubulointerstitial nephropathy with a rare in-
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cidence of urate deposits (Cameron et al. 1993; Puig et
al. 1993; Sebesta et al. 1994; Saeki et al. 1995; Pavelka
et al. 1996; Lhotta et al. 1998). The pathogenesis of the
renal disease is unknown. McBride et al. (1997, 1998)
have provided evidence implicating the hyperuricemia
associated with urate hypoexcretion as being a primary
cause of nephropathy. In contrast, Puig et al. (1993) have
presented data suggesting the opposite mechanism, with
hyperuricemia as a consequence of primary renal he-
modynamics disruption. Other hypotheses have sug-
gested that urate hypoexcretion may be caused either by
a gain-of-function mutation of a luminal anion ex-
changer, leading to intracellular proximal tubular epi-
thelial acidosis and subsequent apoptosis (Lhotta et al.
1998), or by abnormal endogenous production of a
hypothetical protein or metabolite affecting renal urate
handling (Cameron et al. 1993). Therapy with allopu-
rinol, although disputed (Miranda 1994), does seem to
ameliorate the progression of renal damage in a majority
of the patients (Moro et al. 1991; McBride et al. 1998).
This ﬁnding underscores the importance of presympto-
matic diagnosis, especially in children.Mapping the gene
and identifying its defects should facilitate such a di-
agnosis and are thus of great importance.
Three families with FJHNwere included in the present
study. The pedigrees are shown in ﬁgure 1. All of the
Figure 1 Pedigrees of families with FJHN phenotypes used in this study. Haplotypes for markers on chromosome 16 are shown. The haplotype segregating with the disease locus in families A
and B is indicated by a black bar. No haplotype consistent with linkage was found in family C.
Reports 1991
Table 1




LOD SCORE AT v =
0 .01 .05 .1 .2 .3 .4
GATA42E11:
A .96 .95 .88 .80 .63 .44 .23
B 2.62 2.05 1.17 .73 .31 .13 .04
C 3.69 2.51 1.41 .91 .44 .22 .10
D16S499:
A .02 .02 .02 .01 .01 0 0
B 4.15 3.39 2.05 1.34 .66 .31 .11
C .02 .01 .03 .08 .12 .10 .05
D16S501:
A .72 .71 .65 .59 .45 .31 .16
B .06 .32 .67 .77 .72 .54 .30
C 5.56 4.93 3.16 2.12 1.07 .52 .19
D16S3056:
A .92 .91 .85 .78 .61 .43 .23
B .13 .13 .10 .08 .04 .01 0
C 3.64 3.30 2.03 1.28 .58 .27 .11
D16S3041:
A .72 .70 .59 .46 .19 .02 .08
B 4.05 3.98 3.70 3.34 2.57 1.72 .81
C 4.45 3.76 2.42 1.65 .87 .46 .19
D16S3036:
A 1.49 1.46 1.35 1.21 .92 .60 .28
B 4.04 3.97 3.69 3.33 2.56 1.72 .81
C 4.97 4.24 2.46 1.55 .76 .39 .17
D16S3046:
A 1.49 1.46 1.35 1.21 .92 .60 .28
B .75 .73 .67 .60 .45 .31 .16
C 2.82 2.43 1.60 1.22 .64 .37 .17
D16S412:
A .08 .08 .07 .05 .03 .01 0
B .99 .97 .89 .80 .61 .41 .21
C 4.15 3.79 2.47 1.66 .85 .42 .16
D16S403:
A .96 .95 .88 .80 .63 .44 .24
B 1.68 1.65 1.53 1.38 1.07 .75 .39
C 7.01 5.10 2.91 1.8 .79 .3 .07
D16S420:
A .04 .03 .03 .02 .01 0 0
B 2.98 2.93 2.72 2.44 1.85 1.21 .55
C 7.03 5.89 3.69 2.45 1.23 .59 .22
D16S3113:
A 1.19 1.17 1.08 .96 .72 .46 .20
B 1.13 2.11 2.52 2.48 2.05 1.43 .71
C 2.58 1.10 .48 .25 .09 .03 .01
D16S401:
A .96 .95 .88 .80 .63 .44 .23
B 3.13 .19 .95 1.26 1.26 .96 .51
C 6.71 5.51 3.35 2.20 1.09 .54 .21
families are of Czech origin. The diagnosis of FJHNwas
based on characteristic features of the disease, which
include clinical evidence of gouty arthritis or renal fail-
ure, biochemical evidence of hyperuricemia, reduced
fractional excretion of uric acid, and elevated creatinine
serum levels. On the basis of these criteria, 19 affected
individuals (age 7–53 years) were found among 57 in-
dividuals investigated. Urinary purine metabolites were
quantiﬁed, and erythrocyte hypoxanthine-guanine phos-
phoribosyltransferase (HGPRT) and phosphoribosyl-
pyrophosphate synthetase (PRPP) enzyme activities were
measured, to exclude HGPRT deﬁciency and PRPP su-
peractivity in affected individuals. Normal karyotypes
of selected probands from each family were obtained
from phytohemagglutinin-stimulated lymphocytes.After
informed consent was obtained, EDTA blood samples
were collected from individuals informative for linkage
analysis, and DNA was prepared by the DNA Isolation
Kit for Mammalian Blood (Boehringer Mannheim). In
45 individuals, a genomewide scan of 348 microsatellite
markers was commercially genotyped by GeneSeek, rep-
resenting an average spacing of ∼13 cM. The markers
were all part of the version 9 screening set (Center for
Medical Genetics, Marshﬁeld Medical Research Foun-
dation). Reference individuals “1331-01” and “1331-
02” (National Institute of GeneralMedical Sciences’Hu-
man Genetic Mutant Cell Repository) were genotyped
for all markers, as positive controls. For ﬁne mapping
in selected chromosomal regions, the individual markers
were PCR-ampliﬁed by Cy5-labeled upper primers (Ge-
neri Biotech) and were analyzed on an ALFExpress se-
quencer (Pharmacia Upjohn). Genotypes were scored by
DNA Fragment Analyzer software (Pharmacia Upjohn).
The PEDCHECK program (O’Connell and Weeks
1998) was used to screen for errors in genotype data.
Mendelian inconsistencies either were corrected by use
of the original gels or, in cases in which bands could not
be unambiguously resolved, were assigned the genotype
status “unknown.” Two-point and multipoint linkage
analyses were performed by the MLINK and LINKMAP
programs of the FASTLINK software package (Cot-
tingham et al. 1993). The most likely haplotypes for the
markers segregating with the disease were determined
by SIMWALK2 (Sobel and Lange 1996). Tests for ge-
netic heterogeneity, as well as the calculation of LOD
scores in the presence of heterogeneity, were performed
by the HOMOG program (Terwilliger and Ott 1994).
The analysis was performed under the assumption of a
dominant mode of inheritance with 95% penetrance and
.001 frequency of the disease allele. Marker-allele fre-
quencies were estimated on the basis of data on the three
extended families used in this study.
Preliminary results from a two-point genomewide
linkage analysis of 348 microsatellite markers produced
no conclusive proof of linkage; however, two candidate
regions were identiﬁed for further analysis. The ﬁrst re-
gion, on chromosome 4, included markers D4S2394
(maximum two-point LOD score 2.90) and D4S1647
(maximum two-point LOD score 2.01). The second can-
didate region, on chromosome 16, included markers
D16S753 (maximum two-point LOD score 2.25) and
GATA81D12 (maximum two-point LOD score 1.05).
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Table 2
Maximum Values for Two-Point HLOD Scores, v, and a
Marker
Maximum
HLOD Score Maximum v Maximum aa
GATA42E11 .24 0 .25
D16S499 0 0 0
D16S501 .64 .1 .58
D16S3056 .44 0 .48
D16S3041 3.98 0 .63
D16S3036 4.70 0 .66
D16S3046 1.45 0 .63
D16S412 .37 .02 .41
D16S403 1.85 0 .64
D16S420 2.36 0 .49
D16S3113 3.20 .08 1
D16S401 1.30 .1 .63
a Proportion of families in which marker is linked to the disease
locus.
Figure 2 Four-point overlapping HLOD-score analysis of the
four most informative markers in the linked region on chromosome
16. The arrow indicates the 1-LOD-unit conﬁdence interval.
For both of these regions, ﬁne mapping was performed.
Genotyping of additional markers on chromosome 4 did
not provide statistically signiﬁcant LOD scores, whereas
the most likely haplotypes were not consistent with this
region being linked to the disease locus; however, the
additional markers on chromosome 16 indicated linkage
with this region, particularly under the assumption of
genetic heterogeneity among the families.
Two-point LOD scores for the closely spaced markers
on chromosome 16p11.2 are shown in table 1. Visual
inspection of the table suggests that only families A and
B have linkage to the disease locus in this chromosomal
region. A test for genetic heterogeneity at the most in-
formative marker, D16S3036, shows signiﬁcant evidence
of heterogeneity ( ; ). Table 2 shows2x = 7.77 P = .007
maximum LOD scores calculated with allowance for
heterogeneity (HLOD), when only a fraction (a) of fam-
ilies in the sample is assumed to have linkage to the
disease at a given locus (Terwilliger and Ott 1994). For
D16S3036, a maximum two-point HLOD score of 4.70
was obtained at recombination fraction (v) 0 and a =
. The probability that family C has linkage to the.66
disease at this locus, conditional on the estimated values
of a and v, is !.0001. A maximum two-point LOD score
of 5.53 is obtained for D16S3036 ( ) when onlyv = 0
families A and B are considered (i.e., when family C is
excluded from the analysis).
Figure 2 shows overlapping four-point HLOD scores
obtained by use of a subset of the four most informa-
tive markers—D16S499, D16S3041, D16S3036, and
D16S3113. Amaximummultipoint HLOD score of 4.76
is obtained at marker D16S3041 ( ). The 1-LOD-v = 0
unit conﬁdence interval spans a region of ∼10 cM, cen-
tered around D16S3036. The most likely haplotypes are
displayed in ﬁgure 1, along with family pedigrees. Hap-
lotype analysis shows that the entire region delimited by
markers D16S3056 andD16S420 is consistent with link-
age to the disease. Flanking markers D16S501 and
D16S3113 exhibit crossover events with the disease lo-
cus and represent outer boundaries of the linked region
of interest.
The linkage analysis provides several important re-
sults. It localizes the gene involved in FJHN to an ∼10-
cM interval on chromosome 16p11.2. It provides evi-
dence for reduced penetrance of the disease, since that
person III-7 in family B, now age 24 years, who shares
the disease haplotype, initially showed normal clinical
and biochemical results but, during the course of the
investigation, developed repeatedly elevated serum cre-
atinine concentrations. Furthermore, for family C, no
common haplotype was found in the indicated region,
while linkage analysis gave substantial evidence for the
existence of genetic heterogeneity in FJHN. Unfortu-
nately, when we applied linkage analysis exclusively to
family C, we were not able to obtain any signiﬁcant or
even suggestive results from use of the genomewide scan.
Hence, we are able to provide evidence only for the
existence of a second FJHN locus—but no indication as
to its location.
Since familial juvenile gouty nephropathy is associated
with an early onset of hyperuricemia, extremely reduced
fractional uric acid clearance, gouty arthritis, and pro-
gression to renal failure during middle age, its phenotype
can be considered as an extreme form of classical gout
or can be confused with other renal diseases, such as
familial juvenile nephronophthisis type 1 (NPHP1;
2q13), medullary cystic kidney disease type 1 (MCDK1;
1q21), and polycystic kidney disease types 1 (PDK1;
16p13.3) and 2 (PKD2; 4q21-23). On the basis of the
data on family C, we were able to exclude linkage with
the PKD1, PKD2, MCDK1, and NPHP1 regions (when
LOD score !2was used as the criterion).We also noted
that the inheritance pattern observed in pedigree C is
also consistent with an X-linked dominant and/or re-
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cessive segregation. Since such a condition also had been
observed by Westberg et al. (1979), we analyzed the X-
linked markers in family C under both the dominant
and the recessive mode of inheritance; however, no ev-
idence for linkage to the X chromosome was detected.
Interestingly, by using families A and B, we can lo-
calize the FJHN gene to the same linkage interval where
previous studies (Scolari et al. 1999) have localized the
gene for autosomal dominant medullary cystic disease
type 2 (MCKD2 [MIM 603860]). This ﬁnding raises the
question of whether distinct MCDK2 and FJHN genes
are both localized within this region or whether these
two disorders represent two phenotypic forms of a defect
in the same gene. The main clinical features of MCDK2
are small kidneys and numerous corticomedullary and
intramedullary cysts lined by low cuboidal epithelium.
The patients in the family studied by Scolari et al. (1999)
showed features typically diagnostic of MCKD2—but
complicated by hyperuricemia and gouty arthritis. A
similar phenotype was reported also in other families
(Thompson et al. 1978; Fuchshuber et al. 1998; Stavrou
et al. 1998). Contrary to the situation with MCKD, the
presence of renal cysts among the patients with FJHN
is quite rare. We ﬁnd this clinical difference as being
suggestive that FJHN and MCKD may be caused by
defects in two distinct genes. Hence, phenotypic dis-
tinctions must be considered in the evaluation of families
that must be analyzed in order to narrow the critical
genomic interval for FJHN. Our data provide a foun-
dation for further analysis, and progress should be rel-
atively straightforward, since more pedigrees with FJHN
are known and some of them are currently under study
(Greener et al. 1999). The ultimate goal—the identiﬁ-
cation of the FJHN gene—should be greatly facilitated,
since the critical genomic region has been almost com-
pletely sequenced and transcriptionally characterized
(Loftus et al. 1999).
However, since several theories as to the causes of
FJHN have been proposed, and since the pathogenesis
of the disease is not clear at present, identiﬁcation of the
candidate gene(s) is difﬁcult. A search through databases
has identiﬁed several kidney-expressed genes, two of
which seem to be the strongest potential candidates. The
ﬁrst of these is uromodulin (Pook et al. 1993), which is
the most abundant protein in normal human urine and
plays an important role in both ion transport and the
maintenance of water impermeability (Hoyer and Seiler
1979). Furthermore, it has been reported as inﬂuenc-
ing many pathological conditions, such as formation of
kidney stones (Gokhale et al. 1996) and development of
interstitial nephritis and tubular blockade (Resnick
et al. 1978). The other interesting candidate is the mu-
crystallin homologue—NADP-regulated thyroid-hor-
mone–binding protein (THBP) (Vie et al. 1996, 1997).
Thyroid-hormone homeostasis plays an important role
in kidney growth, renal hemodynamics, tubular func-
tion, and electrolyte excretion (Katz and Lindheimer
1977), and association of hyperuricemia with both hy-
pothyroidism (Klein and Levey 1984; Mooraki and Bas-
tani 1998) and hyperthyroidism (Sato et al. 1995) has
been reported. Of the other genes located within the
deﬁned critical region and expressed in the kidney, the
rat hypertension-associated homologue SAH (Iwai et al.
1994) and those for the sodium-permeable non–voltage-
sensitive ion channels, SCNN1B and SCNN1G, also can
be considered but do not represent an immediate, ob-
vious candidate for mutation analysis. We are hoping
that linkage analyses of the additional available families
with FJHN will sufﬁciently narrow the candidate region
to permit sequencing of one or more of the putative genes
and, possibly, help to resolve the issue of the distinctness
of the FJHN and MCKD2 loci.
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